Structure Therapeutics Inc. expected to post a loss of 59 cents a share - Earnings Preview
Structure Therapeutics Inc. GPCR.O is expected to show no change in quarterly revenue when it reports results on November 11 for the period ending December 31 2026
LSEG's mean analyst estimate for Structure Therapeutics Inc. is for a loss of 59 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 14.2% in the last three months.
Wall Street's median 12-month price target for Structure Therapeutics Inc. is $110.00, about 440.5% above its last closing price of $20.35
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2026 | -0.55 | -0.58 | |||
Jun. 30 2026 | -0.40 | -0.40 | -0.49 | Missed | -23.2 |
Mar. 31 2026 | -0.31 | -0.35 | -0.35 | Met | -0.8 |
Dec. 31 2025 | -0.44 | -0.47 | -1.22 | Missed | -162.2 |
Sep. 30 2025 | -0.39 | -0.35 | -1.11 | Missed | -215.9 |
Jun. 30 2025 | -0.29 | -0.28 | -1.08 | Missed | -291.6 |
Mar. 31 2025 | -0.22 | -0.23 | -0.81 | Missed | -253.9 |
Dec. 31 2024 | -0.23 | -0.22 | -0.69 | Missed | -208.3 |
This summary was machine generated November 9 at 22:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)